{"filings":[{"id":100205,"accession_number":"0001493152-26-005074","cik":1011060,"company_name":"Nordicus Partners Corp","ticker":"NORD","form_type":"8-K","filed_at":"2026-02-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Nordicus Partners establishes board committees, appoints members and chairs","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Audit Committee: Kim Mücke (Chair, financial expert), Andrew J. Ritter, Peter Severin.","Compensation Committee: Andrew J. Ritter (Chair), Kim Mücke, Peter Severin.","Nominating Committee: Peter Severin (Chair), Andrew J. Ritter, Kim Mücke.","Charters for Audit, Compensation, and Nominating Committees adopted on November 10, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":75742476.99999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100204,"accession_number":"0001493152-26-000353","cik":1011060,"company_name":"Nordicus Partners Corp","ticker":"NORD","form_type":"8-K","filed_at":"2026-01-05T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Nordicus Partners raises ~$360k via issuance of 131k restricted shares at $2.75/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 131,000 restricted shares to ten private investors at $2.75 per share.","Private placement closed on January 5, 2026; shares were issued in December 2025.","Exempted under Section 4(a)(2), Rule 506(b)/(c), and Regulation S.","No underwriters or commissions; securities subject to transfer restrictions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":75742476.99999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116538,"accession_number":"0001493152-25-026281","cik":1011060,"company_name":"Nordicus Partners Corp","ticker":"NORD","form_type":"8-K","filed_at":"2025-12-05T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Nordicus Partners closes private placement of 416,000 shares at $2.75 each","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 416,000 restricted common shares to eight private investors at $2.75/share.","Offering closed December 5, 2025; no underwriters or placement agents used.","Exemption claimed under Section 4(a)(2) and Regulation D (Rule 506) for accredited investors.","Shares unregistered and subject to transfer restrictions; proceeds not disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":75742476.99999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132993,"accession_number":"0001493152-25-014113","cik":1011060,"company_name":"Nordicus Partners Corp","ticker":"NORD","form_type":"8-K","filed_at":"2025-09-19T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Nordicus Partners closes private placement of 1,057,500 shares at $1.90 to 54 investors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 1,057,500 restricted common shares at $1.90 per share from July to September 2025; closed Sept 18, 2025.","Shares issued to 54 accredited investors and non-U.S. persons under Section 4(a)(2), Regulation D, and Regulation S.","No underwriters or agents; no general solicitation; shares subject to transfer restrictions.","Total capital raised approximately $2.01 million (1,057,500 shares × $1.90)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":75742476.99999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132992,"accession_number":"0001641172-25-022954","cik":1011060,"company_name":"Nordicus Partners Corp","ticker":"NORD","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Nordicus Partners furnishes independent valuations for Orocidin and Bio-Convert subsidiaries","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Stanton Park Advisors LLC prepared valuation reports for Orocidin's QR-01 and Bio-Convert's QR-02 as of June 30, 2025.","The valuations are intended for Board evaluation of fair market value and should not be relied upon for other purposes.","No specific valuation figures are disclosed in the filing; exhibits are placeholders only."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":75742476.99999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132991,"accession_number":"0001641172-25-022537","cik":1011060,"company_name":"Nordicus Partners Corp","ticker":"NORD","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Nordicus appoints three new directors after Keller resignation","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Henrik Keller resigned from Board effective August 7, 2025 to pursue other interests.","Board increased from three to five; Torben Jensen, Kim T. Mücke, Andrew J. Ritter appointed.","Jensen is a major shareholder and former GK Partners Senior Partner; Mücke is a Danish state authorized public accountant.","Each new director receives $10,000 annual cash retainer; Jensen and Mücke get 25,000 options, Ritter gets 50,000 at $1.90/share.","Options are fully vested incentive stock options under Nordicus' 2024 Stock Incentive Plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":75742476.99999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132990,"accession_number":"0001641172-25-017697","cik":1011060,"company_name":"Nordicus Partners Corp","ticker":"NORD","form_type":"8-K","filed_at":"2025-07-03T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Nordicus Partners issues 35,000 restricted shares at $4.00 in private placement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 35,000 restricted common shares on June 16, 2025 at $4.00/share, raising $140,000.","Offering exempt under Section 4(a)(2), Rule 506(b)/(c), and Regulation S for non-U.S. investors.","Shares not registered; transfer restrictions and legends apply; no underwriters or commissions paid.","Private placement closed on June 30, 2025; no general solicitation used."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":75742476.99999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132989,"accession_number":"0001641172-25-017351","cik":1011060,"company_name":"Nordicus Partners Corp","ticker":"NORD","form_type":"8-K","filed_at":"2025-07-01T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Nordicus Partners approves one-year CEO and CFO pay packages of $360K and $120K","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Henrik Rouf's amended employment agreement provides base salary of $360,000/year for one year starting July 1, 2025.","CFO Bennett J. Yankowitz's amended consulting agreement provides base salary of $120,000/year for one year starting July 1, 2025.","Both agreements are third amendments to prior agreements dated September 5, 2023, as amended April 1, 2024.","Each agreement has a term of one year, expiring July 1, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":75742476.99999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149549,"accession_number":"0001641172-25-014640","cik":1011060,"company_name":"Nordicus Partners Corp","ticker":"NORD","form_type":"8-K","filed_at":"2025-06-11T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Nordicus Partners issues 54,000 restricted shares at $5.00 each in private placement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 54,000 restricted shares of common stock at $5.00/share to two private investors in April and May 2025.","Private offering closed on June 11, 2025; shares unregistered under Securities Act.","Exemptions claimed under Section 4(a)(2), Rule 506(b)/(c), and Regulation S."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":75742476.99999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149548,"accession_number":"0001641172-25-002086","cik":1011060,"company_name":"Nordicus Partners Corp","ticker":"NORD","form_type":"8-K","filed_at":"2025-04-01T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Nordicus Partners to present on Bio-Convert A/S; no new financial data in filing","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation to analysts and investors regarding wholly owned subsidiary Bio-Convert A/S on or after April 1, 2025.","Slides attached as Exhibit 99.1 but text not provided; contains summary information with previously disclosed estimates.","No financial condition updates beyond fiscal quarter ended September 30, 2024.","Company undertakes no duty to update the presentation; based on prior SEC filings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":75742476.99999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168622,"accession_number":"0001493152-25-009356","cik":1011060,"company_name":"Nordicus Partners Corp","ticker":"NORD","form_type":"8-K","filed_at":"2025-03-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Nordicus Partners furnishes investor presentation on Orocidin A/S subsidiary","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company filed Regulation FD disclosure to provide a presentation about its wholly owned subsidiary Orocidin A/S.","Presentation will be used with analysts and investors on or after March 6, 2025.","No specific financial data or guidance is disclosed in this filing; slides attached as Exhibit 99.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":75742476.99999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168621,"accession_number":"0001493152-25-000059","cik":1011060,"company_name":"Nordicus Partners Corp","ticker":"NORD","form_type":"8-K","filed_at":"2025-01-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Nordicus Partners files 8-K to furnish investor presentation; no details provided","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company furnishes a presentation to analysts and investors on or after January 2, 2025.","Presentation attached as Exhibit 99.1 but specific content not included in filing text.","No financial updates beyond September 30, 2024 quarter referenced.","Presentation available on company website at nordicuspartners.com."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":75742476.99999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168620,"accession_number":"0001493152-25-000003","cik":1011060,"company_name":"Nordicus Partners Corp","ticker":"NORD","form_type":"8-K","filed_at":"2025-01-02T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Nordicus Partners grants warrant to buy 1M shares at $8.91 floor to Danish investor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued warrant to purchase 1,000,000 shares of common stock to GK Partners ApS on December 30, 2024.","Exercise price equals the greater of $8.91 or VWAP on trading day before expiration notice; expires Dec 31, 2025.","Warrant sold in reliance on Section 4(a)(2) and Regulation S; no sales commissions paid.","Warrant shares subject to anti-dilution adjustments including stock splits and subsequent equity sales at lower prices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":75742476.99999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185734,"accession_number":"0001493152-24-048394","cik":1011060,"company_name":"Nordicus Partners Corp","ticker":"NORD","form_type":"8-K","filed_at":"2024-12-03T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Nordicus Partners enters IR consulting agreements with Harbor Access and ESG Advisor Group for cash and restricted stock","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Consulting agreement with Harbor Access LLC for $8,000/month, term through November 30, 2025.","Agreement with ESG Advisor Group for 61,500 restricted shares vesting over 11 months plus bonus milestones.","Shares issued as unregistered securities under Section 4(a)(2) and Rule 506(b)/701 exemption.","No material financial impact disclosed; routine investor relations retention."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":75742476.99999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185733,"accession_number":"0001493152-24-044999","cik":1011060,"company_name":"Nordicus Partners Corp","ticker":"NORD","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["1.01","2.01","3.02","9.01"],"status":"ready","headline":"Nordicus acquires remaining ~5% of Orocidin, making it wholly owned subsidiary","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired 29,663 Orocidin shares (5.34% of outstanding) for 200,000 restricted common shares.","Transaction closed November 12, 2024; Orocidin now 100% owned by Nordicus.","Orocidin is a clinical-stage biopharma developing periodontitis therapies.","Follows Nordicus' May 2024 purchase of 95% of Orocidin."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":75742476.99999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185732,"accession_number":"0001493152-24-044996","cik":1011060,"company_name":"Nordicus Partners Corp","ticker":"NORD","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["1.01","2.01","3.02","9.01"],"status":"ready","headline":"Nordicus Partners acquires 100% of Bio-Convert ApS for 12M restricted shares","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired 100% of Danish clinical-stage biopharma Bio-Convert ApS on Nov 12, 2024.","Consideration: 12 million restricted common shares (OTCQB: NORD) issued to sellers.","Bio-Convert is developing a drug for oral leukoplakia, a potentially malignant disorder.","Nordicus previously acquired 95% of Orocidin A/S in May 2024, adding periodontitis therapy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":75742476.99999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218395,"accession_number":"0001493152-24-022512","cik":1011060,"company_name":"Nordicus Partners Corp","ticker":"NORD","form_type":"8-K","filed_at":"2024-06-04T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Nordicus appoints Peter Severin as chairman after Christian Hill-Madsen resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Christian Hill-Madsen resigned from the board effective June 3, 2024; will remain Chairman of Orocidin A/S (95% owned by Nordicus).","Peter Severin appointed as Chairman; brings 25+ years life sciences sales experience from Novartis, AstraZeneca, GSK.","Board set director compensation: Chairman $20,000/yr, other directors $10,000/yr, payable semiannually from Dec 31, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":75742476.99999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218394,"accession_number":"0001493152-24-020152","cik":1011060,"company_name":"Nordicus Partners Corp","ticker":"NORD","form_type":"8-K","filed_at":"2024-05-16T23:59:59+00:00","items":["1.01","2.01","3.02","9.01"],"status":"ready","headline":"Nordicus acquires 95% of Orocidin A/S for $38M in stock, enters periodontitis market","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired 525,597 Orocidin shares (95% stake) from 11 shareholders for 38M restricted common shares.","Consideration valued at $38M in an all-stock transaction; closed May 13, 2024.","Nordicus CEO Henrik Rouf and Director Henrik Keller join Orocidin's board of directors.","Orocidin is a clinical-stage biopharma developing QR-01 for periodontitis; global market estimated >$1.3B by 2029."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":75742476.99999999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}